Enhancing Renewal Intent Through Value Demonstration

AUTHORS

Aditya Bhandari, Hangmu Mabuhang, Sebika Bomjan Shahi, and Thulani Nsingo
M.S. in Digital Marketing & Media

FACULTY MENTOR

Shimon Perry, MBA

ACKNOWLEDGEMENTS

We would like to express our sincere gratitude to Professor Shimon Perry for his invaluable guidance, expertise, and support throughout this project. We extend our appreciation to Boaz Adler for his valuable industrial guidance and real-world insights. We also thank our Teaching Assistant, Farhana, for her helpful feedback and assistance.

Katz
Katz School of Science and Health

Introduction

Biopharmaceutical R&D budgets are under significant pressure, with Pfizer announcing a **$500M reduction** and Novartis targeting **~$1B in cost savings**. These constraints amplify cost sensitivity in clinical trial analytics and biostatistics services.

Despite strong market positioning, Cytel faces an accelerating renewal challenge driven by competitive disruption and evolving client expectations around measurable ROI.

Problem & Aim

- **Renewal Decline:** 10–15% drop in client renewal intent annually, with 2–7% cost increases compounding client sensitivity
- **ROI Visibility Gap:** Clients lack transparent, measurable ROI data at renewal decision points
- **Competitive Pressure:** Low-cost AI platforms and open-source tools (R, Python) increasingly viable for smaller clients
- **Segment Risk:** Small-to-mid biotech firms — now 55% of FDA approvals — are most vulnerable to churn

Approach

This project used a **value-driven, data-centric approach** to address Cytel's core challenge: the gap between its validated outcomes and clients' perception of return on investment (ROI). The method combined market analysis, customer segmentation, and strategic design to improve retention and expand market access.

Insights were developed using **SWOT (Strengths, Weaknesses, Opportunities, and Threats)** and Porter's Five Forces, along with customer journey mapping. This revealed a key issue: clients lack clear visibility into ROI, especially during renewal decisions.



A dual-strategy framework was proposed to bridge Cytel's validated scientific outcomes with clients' **perception of ROI:**

Value Visibility Strategy	Modular Offering Strategy
1. ROI dashboards and calculator	1. AI-enabled starter tier for SMB biotech
2. "Value Kit" (Case studies + benchmarks)	2. Scalable upgrade pathways to premium
3. Outcomes made financially transparent at renewal	3. Flexible pricing aligned with client size
4. Proactive ROI reporting cadence	4. Reduce barrier for small/mid-tier firms

Implementation:
Phased rollout — research & development → pilot testing & training → refinement → full-scale launch.

Findings

- Client renewal intent decline and annual recurring revenue at risk driven by **growing price sensitivity and competitive encroachment** from lower-cost and AI-enabled market entrants.
- **Potential ROI visibility gap** may be influencing clients' perception of value, contributing to the decline in renewal intent.
- **Converging market pressures** with high buying power, high threat of substitutes, and highly competitive rivalry – suggest Cytel operates in a challenging market, though significant regulatory barriers and credibility provides a competitive edge against new entrants and alternatives.
- **Representation**- Findings are visually represented in the form of a bubble chart plot. This plot illustrates biostatistics specialization depth (y-axis) against global market reach (x-axis), with bubble size representing relative market share.



Conclusions

- **Root Cause Identified:** The renewal gap stems from Cytel's inability to communicate ROI in financially tangible terms at decision-making moments
- **Strategic Fit:** The dual strategy aligns Cytel's validated outcomes with market expectations of measurable value and pricing flexibility
- **SMB Opportunity:** Modular AI-enabled offerings can capture the rapidly growing small biotech segment before competitors do
- **Limitations:** Primary survey data still in progress; ROI benchmarks require validation with Cytel's internal client outcome data

15-25%
Target CSAT Improvement

15%
Renewal Intent Target

70%+
ROI Tool Adoption Goal

SMB
New Segment Access via Modular Tier

References